MedTrace Logo

Renal Assessment for Early Detection of Renal Impairment in Systemic Sclerosis and Systemic Lupus Erythematosus Patients

NCT06287125 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2024-02-29

No results posted yet for this study

Summary

* Evaluate renal resistive index in SSc and SLE patients for early detection of renal impairment.
* Evaluate renal multi-parametric MRI in SSc and SLE patients for early detection of renal impairment.
* Measure the serum levels of CD147 in SSc and SLE patients and its correlation with renal impairment.
* Correlation between detected markers and other assessment tools.

Conditions

  • Systemic Sclerosis and Systemic Lupus Erythematous

Interventions

DEVICE

Renal multi-parametric MRI, Renal doppler ultrasound, Serum CD147

Laboratory investigations: erythrocyte sedimentation rate (ESR) Serum C-reactive protein (CRP) complete blood picture (CBC) liver function tests (LFT): aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin. kidney function tests (KFT): serum creatinine and blood urea. Estimated glomerular filteration rate (eGFR) by CKD-EPI Creatinine Equation (2021). Complete urine analysis for: proteinuria, urinary casts (hyaline, granular), hematuria (RBCs/ high power field), pyuria (WBCs/ high power field). 24 hour protein in urine and Creatinine clearance. Complement 3and 4(C3,C4). Immunological investigations : Antinuclear antibody (ANA) and Anti-double stranded DNA (ds-DNA). Serum CD147 Radiological investigations: * Chest X-ray * Renal Doppler * Multi-parametric MRI

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Nihal Ahmed Fathi, Prof. · Assiut University

  • Marwa Mahmoud Abdelaziz, Prof. · Assiut University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2026-03-01
Completion
2027-03-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06287125 on ClinicalTrials.gov